25 Jul, EOD - Indian

SENSEX 80039.8 (-0.14)

Nifty 50 24406.1 (-0.03)

Nifty Bank 50888.75 (-0.83)

Nifty IT 40055.45 (-0.15)

Nifty Midcap 100 56741.75 (-0.23)

Nifty Next 50 72210.25 (0.51)

Nifty Pharma 21105.5 (0.94)

Nifty Smallcap 100 18673.05 (-0.27)

25 Jul, EOD - Global

NIKKEI 225 37869.51 (-3.28)

HANG SENG 17004.97 (-1.77)

DOW JONES 40360.77 (1.27)

S&P 5478.09 (0.94)

Login/Signup

Corporate News

You are Here : Home > News > Corporate News >

(05 Jun 2024, 16:01)

Torrent Pharmaceuticals enters into patent licensing agreement with Tajeda

To commercialize Vonoprazan in India

Torrent Pharmaceuticals (Torrent) today announced that it has entered into a non-exclusive patent licensing agreement with Takeda to commercialize Vonoprazan in India. Vonoprozan is a novel potassium-competitive acid blocker (P-CAB), used for the treatment of acid related disorders - Gastroesophageal Reflux Disease (GERD). Torrent will market Vonoprazan under its own trademark, Kabvie.

As per a 2019 study published by Indian Journal of Gastroenterology prevalence of GERD in Indian population is around 8.2%, with a higher prevalence of around 11.1% in urban population. According to AWACS MAT April 2024 data, the Indian market for treatments used in GERD is valued at INR 8,064 crore, growing at 8% CAGR over the last 4 years. Currently treatments such as Pantoprazole (Proton Pump Inhi...

More News
More Company News View Company Information